Skip to main content
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Cholangiocarcinoma
Cholangiocarcinoma
Risk Factors for Early Relapse in Patients Undergoing Curative Resection in JCOG1202 Subgroup Analysis
Read More
Cholangiocarcinoma
Characteristics of Long-Term Survivors in the TOPAZ-1 Trial
Read More
Cholangiocarcinoma
IMbrave 151: Atezolizumab With or Without Bevacizumab in Combination With GemCis in Advanced BTC
Read More
Cholangiocarcinoma
Nab-Paclitaxel Plus Sintilimab as Second-Line Treatment for Patients With Advanced BTC: A Phase 2 Study
Read More
Cholangiocarcinoma
Phase 2 Trial of Nivolumab With or Without Ipilimumab Plus SBRT in Patients With Pretreated Advanced BTC
Read More
Cholangiocarcinoma
The Cost-Effectiveness of GemCis With or Without Durvalumab in Patients With Advanced CCA
Read More
Cholangiocarcinoma
NUC-1031 Plus Cisplatin Versus GemCis for First-line Treatment of Advanced BTC, NuTide: 121
Read More
Cholangiocarcinoma
Cross-Comparison of Clinical Trials Assessing Futibatinib and Pemigatinib versus Chemotherapy in Patients with CCA and FGFR2 Fusion or Other Rearrangements
Read More
Cholangiocarcinoma
Utility of Liquid Biopsy for Identification of Molecular Alterations in Solid Tumors
Read More
Cholangiocarcinoma
Preliminary Analyses of QOL Data from the ABC-06 Clinical Trial
Read More
1
2
3
4
5
6
Page 3 of 10
Results 21 - 30 of 99
